Federal Register / Vol. 75, No. 187 / Tuesday, September 28, 2010 / Notices 59731 

consequences: Addiction, overdose, and 

death. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 14, 2010. 

Oral presentations from the public will 

be scheduled between approximately 

10:45 a.m. and 11:45 a.m. on October 

22, 2010. Those desiring to make formal 

oral presentations should notify the 

contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before October 6, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by October 7, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Kalyani 

Bhatt at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 22, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–24251 Filed 9–27–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Subcommittee for Planning the Annual 

Strategic Plan Updating Process of the 

Interagency Autism Coordinating 

Committee (IACC). 

The purpose of the Subcommittee 

meeting is to plan the process for 

updating the IACC Strategic Plan for 

Autism Spectrum Disorder Research. 

The meeting will be open to the public 

and will also be accessible by webinar 

and conference call. 

Name of Committee: Interagency Autism 

Coordinating Committee (IACC). 

Type of meeting: Subcommittee for 

Planning the Annual Strategic Plan Updating 

Process. 

Date: October 6, 2010. 

Time: 9 a.m. to 12 p.m. Eastern Time. 

Agenda: To discuss plans for updating the 

IACC Strategic Plan for ASD Research. 

Place: The National Institute of Mental 

Health, Neuroscience Center, 6001 Executive 

Boulevard, Conference Room 8120, 

Rockville, MD 20852. 

Webinar Access: https:// 

www2.gotomeeting.com/register/927802003. 

Registration: http://www.acclaroresearch.

com/oarc/10–06–10_IACC. Pre-registration is 

recommended to expedite check-in. Seating 

in the meeting room is limited to room 

capacity and on a first come, first served 

basis. 

Conference Call: Dial: 888–848–6715, 

Access code: 5341736. 

Contact Person: Ms. Lina Perez, Office of 

Autism Research Coordination, Office of the 

Director, National Institute of Mental Health, 

NIH, 6001 Executive Boulevard, NSC, Room 

8200, Bethesda, MD 20892–9669, Phone: 

(301) 443–6040, E-mail: 

IACCPublicInquiries@mail.nih.gov. 

Please Note: The meeting will be open to 

the public and accessible via webinar and 

conference call. Members of the public who 

participate using the conference call phone 

number will be able to listen to the meeting 

but will not be heard. If you experience any 

technical problems with the conference call, 

please-mail IACCTechSupport@acclaro

research.com. 

If you experience any technical problems 

with the web presentation tool, please 

contact GoToWebinar at (800) 263–6317. To 

access the web presentation tool on the 

Internet the following computer capabilities 

are required: (A) Internet Explorer 5.0 or 

later, Netscape Navigator 6.0 or later or 

Mozilla Firefox 1.0 or later; (B) Windows® 

2000, XP Home, XP Pro, 2003 Server or Vista; 

(C) Stable 56k, cable modem, ISDN, DSL or 

better Internet connection; (D) Minimum of 

Pentium 400 with 256 MB of RAM 

(Recommended); (E) Java Virtual Machine 

enabled (Recommended). 

Individuals who participate in person or by 

using these electronic services and who need 

special assistance, such as captioning of the 

conference call or other reasonable 

accommodations, should submit a request to 

the Contact Person listed on this notice at 

least 7 days prior to the meeting. 

This notice is being published less than 15 

days prior to the meeting due to the urgent 

need for the Subcommittee to discuss the 

upcoming update of the IACC Strategic Plan 

prior to the IACC meeting scheduled for 

October 22, 2010. 

Schedule is subject to change. 

Information about the IACC is available on 

the Web site: http://www.iacc.hhs.gov. 

Dated: September 22, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–24280 Filed 9–27–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Member 

Conflict Review, Program 

Announcement (PA) 07–318, Initial 

Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

TIME AND DATE: 1 p.m.–3 p.m., November 

15, 2010 (Closed). 

Place: National Institute for 

Occupational Safety and Health 

(NIOSH), CDC, 1095 Willowdale Road, 

Morgantown, West Virginia 26506, 

telephone: (304)285–6143. 

Status: The meeting will be closed to 

the public in accordance with 

provisions set forth in Section 552b(c) 

(4) and (6), Title 5 U.S.C., and the 

Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Public Law 92– 

463. 


srobinson on DSKHWCL6B1PROD with NOTICES
59732 Federal Register / Vol. 75, No. 187 / Tuesday, September 28, 2010 / Notices 

Matters to be Discussed: The meeting 

will include the initial review, 

discussion, and evaluation of ‘‘Member 

Conflict Review, PA 07–318.’’ 

CONTACT PERSON FOR MORE INFORMATION: 

M. Chris Langub, PhD., Scientific 

Review Administrator, Office of 

Extramural Programs, National Institute 

for Occupational Safety and Health, 

CDC, 1600 Clifton Road, NE., Mailstop 

E74, Atlanta Georgia 30333; Telephone: 

(404)498–2543. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: September 20, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–24258 Filed 9–27–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Gastrointestinal Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Gastrointestinal 

Drugs Advisory Committee 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 5, 2010, from 8 a.m. 

to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballroom, 620 

Perry Pkwy., Gaithersburg, MD. The 

hotel telephone number is 301–977– 

8900. 

Contact Person: Kristine T. Khuc, 

Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 31, rm. 2417, Silver Spring, 

MD 20993–0002, 301–796–9001, FAX: 

301–847–8533, email: 

kristine.khuc@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512538. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On November 5, 2010, the 

committee will discuss the results from 

clinical trials of proton pump inhibitors 

in gastroespohageal reflux disease 

(GERD) in patients less than 1 year of 

age, performed in response to a 

Pediatric Written Request under the 

Best Pharmaceuticals for Children Act 

(Nexium, esomeprazole by AstraZeneca 

LP; Prevacid, lansoprazole by Takeda 

Pharmaceuticals North America, Inc; 

Protonix, pantoprazole by Pfizer, Inc.) 

and Pediatric Research Equity Act 

commitment (Prilosec, omeprazole by 

AstraZeneca LP). The pathophysiology 

(disease process) of GERD, its diagnosis 

and management, and issues related to 

the design of clinical trials in this age 

group will be considered. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before October 21, 2010. 

Oral presentations from the public will 

be scheduled between approximately 

1:30 p.m. to 2:30 p.m. Those desiring to 

make formal oral presentations should 

notify the contact person and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before October 13, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

October 14, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Kristine T. 

Khuc at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 22, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–24252 Filed 9–27–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2010–0041] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request, OMB No. 

1660–0036; Federal Emergency 

Management Agency Individual 

Assistance Customer Satisfaction 

Surveys 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice; 30-day notice and 

request for comments; revision of a 

currently approved information 

collection; OMB No. 1660–0036; Caller 

Services Registration Intake Survey, 

FEMA Form 007–0–3 (currently 90– 

147); Caller Services Helpline Survey, 

FEMA Form 007–0–5 (currently 90– 


srobinson on DSKHWCL6B1PROD with NOTICES